Immunotoxin Monotherapy and Combinatorial Therapy With Immune Checkpoint Inhibitors for Malignant Brain Tumors
<p>Glioblastoma is the most common and aggressive malignant brain tumor among all primary brain and central nervous system (CNS) tumors. The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is less than 15 months...
Main Author: | Bao, Xuhui |
---|---|
Other Authors: | Bigner, Darell D |
Published: |
2016
|
Subjects: | |
Online Access: | http://hdl.handle.net/10161/13365 |
Similar Items
-
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
by: Vidyalakshmi Chandramohan, et al.
Published: (2019-05-01) -
PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
by: Yu Zhang, et al.
Published: (2021-03-01) -
Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
by: Michela Guardascione, et al.
Published: (2020-08-01) -
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
by: Barbara Seliger
Published: (2019-05-01) -
Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
by: Mankgopo M. Kgatle, et al.
Published: (2021-04-01)